Research Advance on the Effect of Autophagy on the Survival of Chronic Myeloid Leukemia Cells--Review.
10.19746/j.cnki.issn.1009-2137.2020.06.049
- Author:
Yang YANG
1
,
2
;
Hui-Jun CHEN
1
,
2
;
Jian LI
3
Author Information
1. Key Laboratory of Hematology, The Second Affiliated Hospital of Nanchang University,Nanchang 330006, Jiangxi Province, China
2. Medical Department of Nanchang University Graduate School, Nanchang 330006, Jiangxi Province, China.
3. Key Laboratory of Hematology, The Second Affiliated Hospital of Nanchang University,Nanchang 330006, Jiangxi Province, China,E-mail: ndefy03048@ncu.edu.cn.
- Publication Type:Review
- MeSH:
Apoptosis;
Autophagy;
Drug Resistance, Neoplasm;
Fusion Proteins, bcr-abl;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Protein Kinase Inhibitors/pharmacology*;
Research
- From:
Journal of Experimental Hematology
2020;28(6):2093-2096
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitor (TKI) has significantly improved the treatment of chronic myeloid leukemia (CML), however the resistance often resulted in treatment failure. Currently, it is known that the survival of CML cells can be affected by regulating autophagy, oxidative stress and mitochondrial metabolism, among which autophagy is an evolution-conserved catabolism process, and closely related to the pathogenesis of CML, thus playing a dual role in regulating the biological characteristics of cells. On the one hand, autophagy can promote the apoptosis of CML cells, and also can induce the drug resistance of CML cells on the other hand. In this review, the effect of autophagy on CML cells was summarzed briefly, so as to provide a useful idea to explore the combination of TKI with the autophagy inhibitor or inducer to overcome the resistance of CML to TKI.
